Edgewise Therapeutics Inc [NASDAQ: EWTX] loss -22.90% or -4.61 points to close at $15.52 with a heavy trading volume of 16111698 shares.
The daily chart for EWTX points out that the company has recorded -41.85% loss over the past six months.
If we look at the average trading volume of 1.18M shares, EWTX reached to a volume of 16111698 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Edgewise Therapeutics Inc [EWTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EWTX shares is $42.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EWTX stock is a recommendation set at 1.44. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Scotiabank have made an estimate for Edgewise Therapeutics Inc shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on April 02, 2025. While these analysts kept the previous recommendation, Scotiabank raised their target price to Sector Outperform. The new note on the price target was released on March 07, 2025, representing the official price target for Edgewise Therapeutics Inc stock. Previously, the target price had yet another raise to $30, while Stifel analysts kept a Hold rating on EWTX stock.
The Average True Range (ATR) for Edgewise Therapeutics Inc is set at 2.44 The Price to Book ratio for the last quarter was 3.21, with the Price to Cash per share for the same quarter was set at 4.94.
Trading performance analysis for EWTX stock
Edgewise Therapeutics Inc [EWTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -30.28. With this latest performance, EWTX shares dropped by -36.65% in over the last four-week period, additionally sinking by -41.85% over the last 6 months – not to mention a drop of -13.87% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EWTX stock in for the last two-week period is set at 20.03, with the RSI for the last a single of trading hit 13.86, and the three-weeks RSI is set at 25.17 for Edgewise Therapeutics Inc [EWTX]. The present Moving Average for the last 50 days of trading for this stock 25.84, while it was recorded at 20.87 for the last single week of trading, and 25.46 for the last 200 days.
Edgewise Therapeutics Inc [EWTX]: A deeper dive into fundamental analysis
Edgewise Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 19.93 and a Current Ratio set at 19.93.
Edgewise Therapeutics Inc [EWTX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EWTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Edgewise Therapeutics Inc go to -12.71%.
An analysis of Institutional ownership at Edgewise Therapeutics Inc [EWTX]
There are presently around $111.03%, or 111.55%% of EWTX stock, in the hands of institutional investors. The top three institutional holders of EWTX stocks are: ORBIMED ADVISORS LLC with ownership of 15.02 million shares, which is approximately 16.0634%. RA CAPITAL MANAGEMENT, L.P., holding 8.91 million shares of the stock with an approximate value of $$160.45 million in EWTX stocks shares; and RA CAPITAL MANAGEMENT, L.P., currently with $$114.26 million in EWTX stock with ownership which is approximately 6.7844%.
